2748 T3D2706 Amphetamine Amphetamine is a chiral compound. The racemic mixture can be divided into its optical antipodes: levo- and dextro-amphetamine. Amphetamine is the parent compound of its own structural class, comprising a broad range of psychoactive derivatives, e.g., MDMA (Ecstasy) and the N-methylated form, methamphetamine. Amphetamine is a homologue of phenethylamine. 300-62-9 3007 C9H13N 135.104800 White powder. Volatizes slowly at room temperature Slightly Oral. Amphetamine forms easily absorbed molecules that are highly lipid soluble. Amphetamines stimulate the release of norepinephrine from central adrenergic receptors. At higher dosages, they cause release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems. Amphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). In the periphery, amphetamines are believed to cause the release of noradrenaline by acting on the adrenergic nerve terminals and alpha- and beta-receptors. Modulation of serotonergic pathways may contribute to the calming affect. The drug interacts with VMAT enzymes to enhance release of DA and 5-HT from vesicles. It may also directly cause the reversal of DAT and SERT. Hepatic Half Life: 10 hours LD50: 180 mg/kg (Subcutaneous, Rat) (A308) No indication of carcinogenicity to humans (not listed by IARC). For treatment of Attention Deficit Disorder with Hyperactivity (ADDH) and narcolepsy in children. Prolonged use may cause hallucinations and intense paranoia. Amphetamines are psychologically addictive. Users who stop using them report that they experience various mood problems such as aggression and anxiety and intense cravings for the drugs. Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion. The most common presenting symptoms seen are agitation, hallucinations, suicidal behaviour, and chest pain. Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage, administration of activated charcoal, administration of a cathartic and sedation. (L1712) 2009-07-21T20:26:14Z 2026-05-14T16:24:31Z Amphetamine C07514 2679 CPD-7659 Amphetamine DB00182 true CC(N)CC1=CC=CC=C1 C9H13N InChI=1/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3 InChIKey=KWTSXDURSIMDCE-UHFFFAOYNA-N 135.2062 135.104799421 Exogenous Solid 1.76 HMDB14328 CHEMBL405 13852819 <p>Guohong Wang, &#8220;Composition and methods for synthesis of novel tracers for detecting amphetamine and methamphetamine in samples.&#8221; U.S. Patent US20020090661, issued July 11, 2002.</p> CHEM002138 DTXSID4022600 Oberacher 2011 SI00001700 NS00000406 1-phenylpropan-2-amine